Advanced Pain Control – An innovation in pain control for those suffering from secondary bone cancer

Projektinformationen

APAC

ID Finanzhilfevereinbarung: 866986

DOI

10.3030/866986

Projekt abgeschlossen

EK-Unterschriftsdatum 9 Juni 2019

Startdatum 1 Juli 2019

Enddatum 31 Dezember 2019

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

SCANDINAVIAN CHEMOTECH AB
Sweden

Periodic Reporting for period 1 - APAC (Advanced Pain Control – An innovation in pain control for those suffering from secondary bone cancer)

Berichtszeitraum: 2019-07-01 bis 2019-12-31

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Approximately 25% of all cancer patients are affected by secondary bone cancer, where malignant cells have spread to the bone from other areas. Bone is the third most frequent site of metastasis; a major cause for morbidity, characterized by severe pain, impaired mobility, pathologic fractures, and spinal cord compression. Patients with bone metastasis are treated using systemic therapy and pain control with narcotic analgesics, radiation therapy, and surgery. However, 20–30 % of patients do not respond to conventional treatments and continue to endure great pain and suffering. From a pain perspective, spinal tumours are the worst. Hence there is an unmet need for a treatment that alleviates the unbearable pain experienced by these patients and enables them to lead a more comfortable lifestyle free from debilitating back pain.
The overall objective of this project was to develop and optimize a business plan that will guide the development and commercialization of ChemoTech’s Dynamic-ElectroEnhanced Pain Control™ (D-EEPC), a revolutionary treatment for patients with bone cancer that alleviates pain through tumour bulk reduction

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

ChemoTech performed the feasibility study, which then will guide the overall company business development strategy. It provided a valuable understanding of current trends and opportunities on the bone cancer market, targeted users, and competitive landscape. A work plan for carrying out clinical studies that will prove the concept of electrochemotherapy for the treatment of spine cancer was also developed as part of the project.
The feasibility study has confirmed a clear and large business opportunity within the global bone cancer treatment market and to commercialize our revolutionary medical device for pain reduction in secondary bone cancer.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

This feasibility study has further confirmed the innovative character of ChemoTech’s approach. Our Dynamic-ElectroEnhanced Pain Control™ (D-EEPC) medical device is based on the already marketed IQWave™ platform. It sends short, high voltage electric pulses that, in combination with cytostatic drugs, reduce tumour size and pressure on nerves that cause pain. This medical device will substantially reduce pain associated with secondary bone cancer.
We strive to validate our promising results further and validate the potential for a medical device that will improve treatment, quality of life, decrease healthcare costs and ease the financial burden posed on healthcare budgets. The problem of bone cancer is growing and ChemoTech is convinced its innovative approach will have a significant impact on the burden that bone cancer imposes in Europe and worldwide.

ChemoTech's logo